Reproxalap Shows Promise in Treating Dry Eye Disease by Targeting Ocular Inflammation

Key Insights

• Reproxalap, a novel small molecule drug, inhibits RASP, which are elevated in inflammatory diseases, offering a new approach to reduce ocular inflammation in dry eye disease.
• Clinical trials have demonstrated that reproxalap exhibits statistically significant and clinically relevant activity, suggesting a potentially differentiated product profile.
• Aldeyra Therapeutics is advancing 0.25% topical ocular reproxalap as a lead RASP inhibitor for treating dry eye disease, with studies involving over 1,800 patients.

Aldeyra Therapeutics is developing reproxalap, a novel small molecule drug candidate, for the treatment of dry eye disease by targeting ocular inflammation. Reproxalap functions by inhibiting reactive aldehyde species (RASP), which are elevated in various inflammatory conditions, offering a unique mechanism to diminish ocular inflammation associated with dry eye.

Clinical Efficacy and Safety

Clinical trials involving reproxalap have consistently shown statistically significant and clinically relevant activity. These results suggest that reproxalap may have a commercially differentiated profile compared to currently approved drugs for dry eye disease, potentially offering early and broad activity. Over 1,800 patients have been studied with topical ocular reproxalap, with no significant safety concerns reported; the most common adverse event observed was mild and transient instillation site discomfort.

Addressing Unmet Needs in Dry Eye Disease

If approved, reproxalap has the potential to be the only product that effectively treats dry eye disease, addressing the needs of the large underserved population suffering from this condition. Aldeyra Therapeutics is focusing on advancing a 0.25% topical ocular formulation of reproxalap, their lead RASP inhibitor, through the clinical development and regulatory approval process.